Key Points

  • Asana is scheduled to release its second-quarter fiscal 2026 results after the U.S. market closes on September 3, with Wall Street expecting earnings of $0.09 per share and revenue of approximately $214.15 million. The figures will provide investors with an updated view of demand for the company’s work-management software.
  • The revenue forecast represents a meaningful increase from the $205.09 million reported in the first quarter of fiscal 2026 and would mark continued year-over-year expansion. At the same time, the earnings forecast remains below the pace of recent reported EPS growth, making profitability and operating leverage important areas of focus.
  • Asana has consistently exceeded analyst expectations in the previous four quarters. Revenue surprises ranged from 0.21% to 2.04%, while EPS surprises were significantly stronger, reaching 33.24% in the most recent quarter. Another beat could reinforce expectations that the company is converting stable revenue growth into improving profitability.
hero

Analysts currently expect Asana to generate $214.15 million in second-quarter revenue, compared with $196.94 million in the same quarter a year earlier. That represents an increase of roughly 8.7%, suggesting that the company continues to expand despite operating in a competitive market for collaboration and productivity software.

The forecast also sits above the $205.09 million reported in the first quarter. The progression from $196.94 million in Q2 fiscal 2025 to $201.03 million in Q3, $205.57 million in Q4 and $205.09 million in Q1 indicates a relatively steady upward trajectory, although the pace of growth remains moderate.

Profitability Could Become the Bigger Story

The $0.09 EPS estimate compares with $0.06 in the year-ago quarter and $0.10 in the previous quarter. While the forecast implies substantial year-over-year earnings growth, it would represent a sequential decline from the first-quarter result. Investors may therefore pay close attention to whether Asana can maintain its recent improvements in efficiency and profitability.

The company has exceeded EPS expectations in each of the previous four quarters. Reported EPS came in at $0.06 versus an estimate of $0.05 in Q2 fiscal 2025, followed by $0.07, $0.08 and $0.10 in subsequent quarters. The associated surprises were 20.82%, 12.90%, 13.42% and 33.24%, respectively, creating a track record that could raise expectations for another positive surprise.

Execution Remains Critical for Investors

Asana’s recent results show a company that has been delivering better-than-expected earnings even as revenue growth remains measured. The widening difference between reported and estimated EPS suggests that cost discipline and operating efficiency could be increasingly important to the investment case.

Revenue execution will nevertheless remain critical. A result above $214.15 million would strengthen the case that demand is accelerating, while a miss could renew questions about the company’s ability to generate faster growth in a crowded software market. Investors will also be watching management commentary for signals on customer spending, product adoption and the trajectory of profitability.

What to Watch After the Release

The immediate market reaction is likely to depend on the combination of headline results and forward guidance. A revenue beat accompanied by sustained EPS expansion would provide a constructive signal, particularly given Asana’s recent history of outperforming consensus estimates. Conversely, weaker guidance could overshadow a quarterly beat if investors interpret it as evidence of slower demand ahead.

Asana’s September 3 report therefore represents more than a comparison with the $214.15 million revenue and $0.09 EPS forecasts. The results will help determine whether the company’s recent earnings momentum can continue while revenue growth gradually improves. Investors should focus on the balance between expansion, efficiency and forward expectations as the next phase of Asana’s growth story takes shape.


Comparison, examination, and analysis between investment houses

Leave your details, and an expert from our team will get back to you as soon as possible

    * This article, in whole or in part, does not contain any promise of investment returns, nor does it constitute professional advice to make investments in any particular field.

    To read more about the full disclaimer, click here
    SKN | Could Delta’s Higher Fares Offset Rising Fuel Costs as the Airline Cuts Its 2026 Profit Forecast?
    • omer bar
    • •
    • 8 Min Read
    • •
    • ago 2 days

    SKN | Could Delta’s Higher Fares Offset Rising Fuel Costs as the Airline Cuts Its 2026 Profit Forecast? SKN | Could Delta’s Higher Fares Offset Rising Fuel Costs as the Airline Cuts Its 2026 Profit Forecast?

    Delta Air Lines has lowered its 2026 profit expectations as soaring jet fuel costs weigh on earnings, highlighting the challenge

    • ago 2 days
    • •
    • 8 Min Read

    Delta Air Lines has lowered its 2026 profit expectations as soaring jet fuel costs weigh on earnings, highlighting the challenge

    SKN | Could Samsung’s Record Profit Signal Another Major Phase of the AI Chip Boom?
    • Ronny Mor
    • •
    • 6 Min Read
    • •
    • ago 3 days

    SKN | Could Samsung’s Record Profit Signal Another Major Phase of the AI Chip Boom? SKN | Could Samsung’s Record Profit Signal Another Major Phase of the AI Chip Boom?

    Samsung Electronics is projecting its strongest quarterly profitability on record, underscoring the extraordinary impact that the artificial intelligence boom is

    • ago 3 days
    • •
    • 6 Min Read

    Samsung Electronics is projecting its strongest quarterly profitability on record, underscoring the extraordinary impact that the artificial intelligence boom is

    SKN | Could Summit’s Ivonescimab Help AstraZeneca Build the Next Generation of Cancer Treatments?
    • Ronny Mor
    • •
    • 7 Min Read
    • •
    • ago 6 days

    SKN | Could Summit’s Ivonescimab Help AstraZeneca Build the Next Generation of Cancer Treatments? SKN | Could Summit’s Ivonescimab Help AstraZeneca Build the Next Generation of Cancer Treatments?

    Summit Deal Puts Ivonescimab at the Center of AstraZeneca’s Strategy AstraZeneca is positioning its investment in Summit Therapeutics around the

    • ago 6 days
    • •
    • 7 Min Read

    Summit Deal Puts Ivonescimab at the Center of AstraZeneca’s Strategy AstraZeneca is positioning its investment in Summit Therapeutics around the

    SKN | Could Boeing’s New Fighter Jet Wins Mark a Turning Point for Its Defense Business?
    • Lior mor
    • •
    • 8 Min Read
    • •
    • ago 6 days

    SKN | Could Boeing’s New Fighter Jet Wins Mark a Turning Point for Its Defense Business? SKN | Could Boeing’s New Fighter Jet Wins Mark a Turning Point for Its Defense Business?

    Boeing Expands Its Position in Next-Generation Fighters Boeing has strengthened its position in the U.S. military aircraft market after securing

    • ago 6 days
    • •
    • 8 Min Read

    Boeing Expands Its Position in Next-Generation Fighters Boeing has strengthened its position in the U.S. military aircraft market after securing